+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

G

Actively Recruiting

Researchers are conducting an observational study to learn about the experiences of people living with Myasthenia Gravis MG in the United States. The study aims to understand how and when MG is diagnosed, the common symptoms, treatments used, and the impact of MG on daily activities, employment, and quality of life. It also explores experiences related to disease flare-ups, hospitalizations, and access to healthcare. Participants with MG will join a patient-reported registry where they provide information via surveys. After enrolling through an initial survey, participants are invited to complete update surveys twice a year to share ongoing information about their condition and experiences. Throughout the study, participants will answer surveys that include questions about their diagnosis, symptoms, treatments, and life impacts. The main measurement is confirming the diagnosis of MG at enrollment. The study is led by the Myasthenia Gravis Foundation of America and follows participants over time to gather detailed patient-reported data about living with MG.

Age: 18Years +All Genders
1 location
R

Actively Recruiting

Researchers are evaluating the investigational inhaled migraine medication ASY202 to assess its effectiveness, safety, and tolerability in adults with migraine. This Phase 2 clinical trial uses a randomized, double-blind, placebo-controlled, crossover design, involving adults aged 18 to 65 with a history of migraine. Participants will receive both ASY202 and placebo at different times during the study, without knowing which treatment they are receiving. The study is sponsored by Aspeya, Inc. and aims to better understand how ASY202 works for acute migraine treatment. Participants will use a handheld dry powder inhaler to take ASY202, a pre-metered dry powder formulation of dihydroergotamine DHE, during migraine attacks. The study includes two treatment periods separated by a washout period of at least 7 days. In Treatment Period 1, one group will receive ASY202 followed by placebo in Treatment Period 2, while the other group receives placebo first then ASY202. The placebo is an inactive inhalation powder delivered with a matching inhaler device. During the approximately 16-week study, participants will undergo screening, two treatment periods, and a safety follow-up visit. Researchers will monitor headache pain relief and freedom from pain at various timepoints post-dose, including 2 hours and up to 48 hours, as well as the use of rescue medication and functional ability. Safety assessments will track adverse events from screening through study completion. The study includes multiple visits to evaluate efficacy and tolerability throughout the trial.

Age: 18Years - 65YearsAll GendersPhase 2
20 locations
R

Actively Recruiting

Researchers are evaluating EVO756, a medication taken orally, to study its effects on adults with migraine. This phase 2 trial aims to test the efficacy and safety of two different daily doses of EVO756 compared to a placebo. The study focuses on preventing migraines and is sponsored by Evommune, Inc. Participants will be randomly assigned to one of three groups one receiving daily Dose 1 of EVO756, another receiving daily Dose 2 of EVO756, or a placebo group taking a daily placebo pill. The treatment period lasts 12 weeks, during which participants take their assigned medication every day. Throughout the study, participants will have regular assessments to track changes in the number of monthly migraine and headache days, medication use, and any side effects. The main measurement is the change in monthly migraine days during the last month of treatment. Safety monitoring continues through week 16. The overall study runs from July 2026 to November 2027, with participants involved for at least 12 weeks of treatment and follow-up.

Age: 18Years - 64YearsAll GendersPhase 2
45 locations